See More

See the benefits of home administration

See the benefits of home administration

Aspaveli is the first subcutaneous treatment for PNH that can be self-infused1

Aspaveli is the first subcutaneous treatment for PNH that can be self-infused
  • Aspaveli is administered twice-weekly as a 1080 mg subcutaneous infusion1

Aspaveli can be self-administered using a commercially available infusion pump that can deliver doses up to 20 mL.1

For full preparation and administration information, refer to the Aspaveli Instructions for Use and the infusion pump manufacturer’s instructions.

PNH=paroxysmal nocturnal haemoglobinuria.

Reference: 1. Aspaveli (pegcetacoplan) Summary of Product Characteristics. 2021.